EyeBrain, a company developing medical devices for the early diagnosis of neurological diseases, announces today that its EyeBrain Tracker device is being used in a clinical trial exploring the dyskinesia induced by treating patients suffering from idiopathic Parkinson’s disease with levodopa.
The endpoint of the trial is to find biomarkers for the late-onset complications of a treatment regime using levodopa (BIODYS). This compound, which is naturally transformed into dopamine in the brain, is one of the only drugs available for slowing the effects of Parkinson’s disease. However, over time, it induces dyskinesia in these patients, which takes the form of abnormal movements primarily affecting the face (tongue, lips, jaw) and extending as far as the arms and legs.
Altogether, 30 people will be enrolled on the trial. Half of them will be Parkinson’s sufferers who have been treated with levodopa and have developed dyskinesia, while the other half will consist of healthy subjects who will be used as a control group.
The trial is being sponsored and financed by Bordeaux University Hospital and was set up by professor Jean-François Tison, a neurologist attached to the CNRS Physiopathology of Parkinsonian syndromes unit at the University of Bordeaux Two (the Institute of Neurodegenerative Diseases, CNRS UMR 5293E, Bezard). The EyeBrain Tracker device is being funded under the joint 2007-2013 State-Region Plan (Aquitaine Regional Council and the FEDER fund).
“Patients suffering from idiopathic Parkinson’s disease will undergo an acute test as part of a pre-operational assessment for stimulating the deep recesses of the brain,” explained professor Tison. The motricity effects of the treatment will be evaluated by measuring the speed of eye movements with the help of the EyeBrain Tracker.
“We will see whether levodopa modifies the parameters of blinking in a way that is correlated with the improvement in motricity,” said professor Tison. “Using the EyeBrain Tracker enables us to measure the motricity effect through eye movements, since the blinking parameters are also linked to the patient’s general motricity. The patient’s response to this trial is also a predictor of their reaction to the neurosurgery that will follow.”
The EyeBrain Tracker, which is already used in the early diagnosis of Parkinsonian syndromes, such as progressive supra-nuclear paralysis (PSP), cortico-basal degeneration (CBD) and multiple systems atrophy (MSA), is thus continuing to broaden its fields of application. It is now playing an important role in clinical research into other neurological diseases, such as multiple sclerosis, and is a valuable aid in the early diagnosis and follow-up of these diseases.
“We are delighted to know that the EyeBrain Tracker is playing a part in a clinical trial targeting idiopathic Parkinson’s,” said the chairman of EyeBrain, Serge Kinkingnéhun. “This forms part of our goal of making the benefits of eye motricity available to a larger number of people suffering from neurological pathologies.”
Parkinson’s disease is the second most common neurodegenerative disease after Alzheimer’s. In western countries it affects 0.3 per cent of the general population. Its prevalence increases with age, reaching one per cent in the over-60s, and as much as four per cent in the over-80s. There are 100,000 sufferers in France and 8,000 new cases are diagnosed each year.About EyeBrain
The Mobile EyeBrain Tracker (EBT) comes as a complete solution including headphones, a computer with two screens and stimulation and analysis software. It is already being used routinely in hospitals to help with the early characterization of Parkinsonian syndromes. Studies are also underway for the diagnosis of multiple sclerosis (MS).
The Mobile EBT is the only device of its kind in the world to have obtained CE marking. The company has ISO 9001 and ISO 13485 certification.
EyeBrain, which is based in the Paris suburb of Ivry-sur-Seine, was founded in 2008 and currently employs 15 people. It has raised funding of EUR 1.2 million from the CapDecisif and G1J venture capital funds and already generates revenues through the sale of the EyeBrain Tracker. It is engaged in collaborations with the French National Health and Medical Research Institute (INSERM), the French National Scientific Research Center (CNRS), Paris University Hospitals group, the University of Paris-Descartes and the French Brain and Spinal Cord Institute.For further information about the company, go to: http://www.eye-brain.com
Lucie Nguyen | Andrew Lloyd & Associates
Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University
The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water
In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
05.12.2016 | Power and Electrical Engineering
05.12.2016 | Materials Sciences
05.12.2016 | Power and Electrical Engineering